Iberdomide hydrochloride is a Small Molecule owned by Bristol-Myers Squibb, and is involved in 21 clinical trials, of which 1 was completed, 12 are ongoing, and 8 are planned.
Iberdomide hydrochloride binds to CRBN and inhibits CRBN ubiquitination and enhances T cell IL-2 production, but inhibits B cell production of immunoglobulin. The CRBN-DDB1-Cul4-Roc1 E3 ubiquitin ligase complex functions as a substrate receptor in which the proteins recognized by CRBN are ubiquitinated and subsequently degraded by proteasomes. CRBN plays an important role in binding, ubiquitination and degradation of factors involved in inflammation. IKZF1 and IKZF3 are transcription factors central to the differentiation of lympho-myeloid multipotent progenitor cells through mature immune cells, including T cells and B cells. The degradation of IKZF1 and IKZF3 leads to enhanced T cell activity that exerts anti-cancer effects.
The revenue for Iberdomide hydrochloride is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Iberdomide hydrochloride NPV Report.
Iberdomide hydrochloride Overview
Iberdomide hydrochloride (CC-220) is under development for the treatment of systemic lupus erythematosus, relapsed/refractory multiple myeloma, aggressive B-cell lymphoma, B-cell lymphoma, unspecified B-cell lymphomas, T-cell lymphoma, natural killer (NK)-cell non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), marginal zone lymphoma (MZL), extranodal marginal zone b-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma, nodal marginal zone b-cell lymphoma, splenic marginal zone b-cell lymphoma, mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma, and classical Hodgkin lymphoma (CHL). The drug candidate is administered orally. It targets cereblon (CRBN) and inhibits CRBN ubiquitination. The drug candidate is an immunomodulatory imide drug (IMiD). It was also under development for cutaneous lupus erythematosus, systemic sclerosis and chronic cutaneous sarcoidosis.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.
Quick View – Iberdomide hydrochloride
|Highest Development Stage|